Literature DB >> 33169016

Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome.

Robert W Davies1,2, Ania M Fiksinski3,4, Elemi J Breetvelt5, Nigel M Williams6, Stephen R Hooper7, Thomas Monfeuga6, Anne S Bassett4,8,9, Michael J Owen6, Raquel E Gur10, Bernice E Morrow11, Donna M McDonald-McGinn12,13, Ann Swillen14,15, Eva W C Chow4,8, Marianne van den Bree6, Beverly S Emanuel12, Joris R Vermeesch14, Therese van Amelsvoort16, Celso Arango17, Marco Armando18, Linda E Campbell19, Joseph F Cubells20,21, Stephan Eliez18, Sixto Garcia-Minaur22, Doron Gothelf23,24, Wendy R Kates25, Kieran C Murphy26, Clodagh M Murphy27, Declan G Murphy27, Nicole Philip28,29, Gabriela M Repetto30, Vandana Shashi31, Tony J Simon32, Damiàn Heine Suñer33, Stefano Vicari34, Stephen W Scherer35, Carrie E Bearden36, Jacob A S Vorstman37,38,39.   

Abstract

The 22q11.2 deletion syndrome (22q11DS) is associated with a 20-25% risk of schizophrenia. In a cohort of 962 individuals with 22q11DS, we examined the shared genetic basis between schizophrenia and schizophrenia-related early trajectory phenotypes: sub-threshold symptoms of psychosis, low baseline intellectual functioning and cognitive decline. We studied the association of these phenotypes with two polygenic scores, derived for schizophrenia and intelligence, and evaluated their use for individual risk prediction in 22q11DS. Polygenic scores were not only associated with schizophrenia and baseline intelligence quotient (IQ), respectively, but schizophrenia polygenic score was also significantly associated with cognitive (verbal IQ) decline and nominally associated with sub-threshold psychosis. Furthermore, in comparing the tail-end deciles of the schizophrenia and IQ polygenic score distributions, 33% versus 9% of individuals with 22q11DS had schizophrenia, and 63% versus 24% of individuals had intellectual disability. Collectively, these data show a shared genetic basis for schizophrenia and schizophrenia-related phenotypes and also highlight the future potential of polygenic scores for risk stratification among individuals with highly, but incompletely, penetrant genetic variants.

Entities:  

Mesh:

Year:  2020        PMID: 33169016      PMCID: PMC7975627          DOI: 10.1038/s41591-020-1103-1

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   87.241


  50 in total

1.  Childhood neuromotor dysfunction in schizophrenia patients and their unaffected siblings: a prospective cohort study.

Authors:  I M Rosso; C E Bearden; J M Hollister; T L Gasperoni; L E Sanchez; T Hadley; T D Cannon
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

2.  Childhood precursors of schizophrenia: facial expressions of emotion.

Authors:  E F Walker; K E Grimes; D M Davis; A J Smith
Journal:  Am J Psychiatry       Date:  1993-11       Impact factor: 18.112

3.  Premorbid IQ in schizophrenia: a meta-analytic review.

Authors:  Kristen A Woodberry; Anthony J Giuliano; Larry J Seidman
Journal:  Am J Psychiatry       Date:  2008-04-15       Impact factor: 18.112

4.  Course of Cognitive Development From Infancy to Early Adulthood in the Psychosis Spectrum.

Authors:  Josephine Mollon; Anthony S David; Stanley Zammit; Glyn Lewis; Abraham Reichenberg
Journal:  JAMA Psychiatry       Date:  2018-03-01       Impact factor: 21.596

5.  Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.

Authors:  Abraham Reichenberg; Avshalom Caspi; Honalee Harrington; Renate Houts; Richard S E Keefe; Robin M Murray; Richie Poulton; Terrie E Moffitt
Journal:  Am J Psychiatry       Date:  2010-01-04       Impact factor: 18.112

6.  Meta-analyses of cognitive and motor function in youth aged 16 years and younger who subsequently develop schizophrenia.

Authors:  H Dickson; K R Laurens; A E Cullen; S Hodgins
Journal:  Psychol Med       Date:  2011-09-06       Impact factor: 7.723

7.  A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia.

Authors:  Golam M Khandaker; Jennifer H Barnett; Ian R White; Peter B Jones
Journal:  Schizophr Res       Date:  2011-07-18       Impact factor: 4.939

8.  A longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses.

Authors:  Stanley Zammit; Peter Allebeck; Anthony S David; Christina Dalman; Tomas Hemmingsson; Ingvar Lundberg; Glyn Lewis
Journal:  Arch Gen Psychiatry       Date:  2004-04

9.  Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study in males.

Authors:  James H MacCabe; Susanne Wicks; Sofia Löfving; Anthony S David; Åsa Berndtsson; Jan-Eric Gustafsson; Peter Allebeck; Christina Dalman
Journal:  JAMA Psychiatry       Date:  2013-03       Impact factor: 21.596

Review 10.  Early interventions in risk groups for schizophrenia: what are we waiting for?

Authors:  Iris E Sommer; Carrie E Bearden; Edwin van Dellen; Elemi J Breetvelt; Sasja N Duijff; Kim Maijer; Therese van Amelsvoort; Lieuwe de Haan; Raquel E Gur; Celso Arango; Covadonga M Díaz-Caneja; Christiaan H Vinkers; Jacob As Vorstman
Journal:  NPJ Schizophr       Date:  2016-03-09
View more
  27 in total

Review 1.  Genomics, convergent neuroscience and progress in understanding autism spectrum disorder.

Authors:  Helen Rankin Willsey; A Jeremy Willsey; Belinda Wang; Matthew W State
Journal:  Nat Rev Neurosci       Date:  2022-04-19       Impact factor: 34.870

2.  Prognostic value of polygenic risk scores for adults with psychosis.

Authors:  Isotta Landi; Deepak A Kaji; Liam Cotter; Tielman Van Vleck; Gillian Belbin; Michael Preuss; Ruth J F Loos; Eimear Kenny; Benjamin S Glicksberg; Noam D Beckmann; Paul O'Reilly; Eric E Schadt; Eric D Achtyes; Peter F Buckley; Douglas Lehrer; Dolores P Malaspina; Steven A McCarroll; Mark H Rapaport; Ayman H Fanous; Michele T Pato; Carlos N Pato; Tim B Bigdeli; Girish N Nadkarni; Alexander W Charney
Journal:  Nat Med       Date:  2021-09-06       Impact factor: 53.440

3.  Contribution of schizophrenia polygenic burden to longitudinal phenotypic variance in 22q11.2 deletion syndrome.

Authors:  Maris Alver; Valentina Mancini; Kristi Läll; Maude Schneider; Luciana Romano; Reedik Mägi; Emmanouil T Dermitzakis; Stephan Eliez; Alexandre Reymond
Journal:  Mol Psychiatry       Date:  2022-06-29       Impact factor: 13.437

Review 4.  A genetics-first approach to understanding autism and schizophrenia spectrum disorders: the 22q11.2 deletion syndrome.

Authors:  Ania M Fiksinski; Gil D Hoftman; Jacob A S Vorstman; Carrie E Bearden
Journal:  Mol Psychiatry       Date:  2022-10-03       Impact factor: 13.437

5.  Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia.

Authors:  Todd Lencz; Jin Yu; Raiyan Rashid Khan; Erin Flaherty; Shai Carmi; Max Lam; Danny Ben-Avraham; Nir Barzilai; Susan Bressman; Ariel Darvasi; Judy H Cho; Lorraine N Clark; Zeynep H Gümüş; Joseph Vijai; Robert J Klein; Steven Lipkin; Kenneth Offit; Harry Ostrer; Laurie J Ozelius; Inga Peter; Anil K Malhotra; Tom Maniatis; Gil Atzmon; Itsik Pe'er
Journal:  Neuron       Date:  2021-03-22       Impact factor: 17.173

Review 6.  Diagnostic genetic testing for neurodevelopmental psychiatric disorders: closing the gap between recommendation and clinical implementation.

Authors:  Brenda M Finucane; David H Ledbetter; Jacob As Vorstman
Journal:  Curr Opin Genet Dev       Date:  2021-01-09       Impact factor: 5.578

Review 7.  Pathways to understanding psychosis through rare - 22q11.2DS - and common variants.

Authors:  Raquel E Gur; David R Roalf; Aaron Alexander-Bloch; Donna M McDonald-McGinn; Ruben C Gur
Journal:  Curr Opin Genet Dev       Date:  2021-02-08       Impact factor: 5.578

8.  Editorial overview: Rare CNV disorders and neuropsychiatric phenotypes: opportunities, challenges, solutions.

Authors:  Jennifer Gladys Mulle; Patrick F Sullivan; Jens Hjerling-Leffler
Journal:  Curr Opin Genet Dev       Date:  2021-05-28       Impact factor: 5.578

Review 9.  A cross-comparison of cognitive ability across 8 genomic disorders.

Authors:  Michael Mortillo; Jennifer G Mulle
Journal:  Curr Opin Genet Dev       Date:  2021-05-31       Impact factor: 4.665

Review 10.  Harnessing rare variants in neuropsychiatric and neurodevelopment disorders-a Keystone Symposia report.

Authors:  Jennifer Cable; Ryan H Purcell; Elise Robinson; Jacob A S Vorstman; Wendy K Chung; John N Constantino; Stephan J Sanders; Mustafa Sahin; Ricardo E Dolmetsch; Bina Maniar Shah; Audrey Thurm; Christa L Martin; Carrie E Bearden; Jennifer G Mulle
Journal:  Ann N Y Acad Sci       Date:  2021-08-02       Impact factor: 6.499

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.